Clinically Relevant Biomarkers to Select Patients for Targeted Inhibitor Therapy after Resection of Hepatocellular Carcinoma

Molecularly targeted therapy in hepatocellular carcinoma

(2010) Hung Huynh   BIOCHEMICAL PHARMACOLOGY

Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib

(2010) Thomas Yau et al.   EXPERT OPINION ON PHARMACOTHERAPY

Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06)

(2010) D. Koeberle et al.   ONCOLOGIST

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

PDGFRα: a new therapeutic target in the treatment of hepatocellular carcinoma?

(2009) Abdul M Oseini et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

(2009) Andrew X. Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

(2009) Sandrine Faivre et al.   LANCET ONCOLOGY

Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond milan criteria

(2009) Federico Aucejo et al.   LIVER TRANSPLANTATION

Evaluation of Model for End Stage Liver Disease (MELD)-based systems as prognostic index for hepatocellular carcinoma

(2008) Jenny L Limquiaco et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Changing management and outcome of hepatocellular carcinoma: Evaluation of 501 patients treated at a single comprehensive center

(2008) David A. Kooby et al.   JOURNAL OF SURGICAL ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE